St. Louis, MO, May 16, 2018 – Acera Surgical, a leader in implantable nanomedical scaffolds, is pleased to announce its support as the sponsor of the third annual Saint Louis University Wound Healing Symposium, to be held on May 24th from 9 a.m. to noon in the 9th floor conference room of the Doisy Research Center on the University campus.
This symposium is designed to bring together faculty with complementary research interests to further the wound healing community. Expected attendees include clinicians, wound care coordinators, nurses, and researchers focused on developing and implementing new solutions in wound care. Dr. Devin Bland, Chief of Podiatry at Tuba City Regional Medical Center in Tuba City, AZ will be the clinical keynote speaker for the event, offering his perspective on advances in treating chronic lower extremity wounds. Dr. Matthew MacEwan, Chief Science Officer of Acera Surgical, Inc., will be the scientific keynote speaker and will be discussing applications of material science in chronic wound care.
“We are extremely excited to support the third annual Saint Louis University Wound Healing Symposium and its critical role in the local wound care community in the Saint Louis region,” said Dr. Matthew MacEwan, President and Chief Scientific Officer of Acera Surgical. “The exchange of new concepts and ideas between basic science and clinical researchers across multiple institutions is key to improving the overall quality of our local healthcare ecosystem.”
About Saint Louis University
Founded in 1818, Saint Louis University (SLU) was the first institution of higher education west of the Mississippi River. SLU is rated among the nation’s top 100 research universities. SLU offers more than 20 graduate and undergraduate programs that are ranked within the top 100 in the country by U.S. News & World Report. SLU currently employs over 3,200 faculty members and has an impressive endowment of $1.1 billion.
About Acera Surgical Inc.
Acera Surgical Inc. (“Acera,” St. Louis, Missouri) is a bioscience company commercializing a portfolio of implantable nanomedical scaffolds for medical applications. Acera’s products exhibit a structure similar to native extracellular matrix (ECM) and thus support rapid and effective healing. Acera is currently commercializing its first two products, the Cerafix® Dural Substitute and the Restrata® Wound Matrix, both FDA cleared via 510(k).
For additional information on Acera Surgical or the Restrata® Wound Matrix, please visit www.acera-surgical.com.